MPTP: clinical implications.
The concept of selective vulnerability of the basal ganglia is briefly reviewed historically, with respect to the possible implications of MPTP and also the possible protective effects of selective MOA inhibition in the treatment of Parkinson's disease.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000368:Aged; D001479:Basal Ganglia / Q000187:drug effects*; D001545:Benserazide / Q000008:administration & dosage*; D004338:Drug Combinations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage*; D007980:Levodopa / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology; D010627:Phenethylamines / Q000008:administration & dosage*; D011725:Pyridines / Q000494:pharmacology*; D012642:Selegiline / Q000008:administration & dosage*
D004338:Drug Combinations; D006834:Hydrazines; D010627:Phenethylamines; D011725:Pyridines; C005177:benserazide, levodopa drug combination; D012642:Selegiline; D007980:Levodopa; D001545:Benserazide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine